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a b s t r a c t
We present a framework for simulating cross-sectional or longitudinal biomarker data sets from neurode-
generative disease cohorts that reﬂect the temporal evolution of the disease and population diversity. The
simulation system provides a mechanism for evaluating the performance of data-driven models of disease
progression, which bring together biomarker measurements from large cross-sectional (or short term longi-
tudinal) cohorts to recover the average population-wide dynamics. We demonstrate the use of the simula-
tion framework in two different ways. First, to evaluate the performance of the Event Based Model (EBM) for
recovering biomarker abnormality orderings from cross-sectional datasets. Second, to evaluate the perfor-
mance of a differential equation model (DEM) for recovering biomarker abnormality trajectories from short-
term longitudinal datasets. Results highlight several important considerations when applying data-driven
models to sporadic disease datasets as well as key areas for future work. The system reveals several impor-
tant insights into the behaviour of each model. For example, the EBM is robust to noise on the underlying
biomarker trajectory parameters, under-sampling of the underlying disease time course and outliers who
follow alternative event sequences. However, the EBM is sensitive to accurate estimation of the distribution
of normal and abnormal biomarker measurements. In contrast, we ﬁnd that the DEM is sensitive to noise on
the biomarker trajectory parameters, resulting in an over estimation of the time taken for biomarker trajecto-
ries to go from normal to abnormal. This over estimate is approximately twice as long as the actual transition
time of the trajectory for the expected noise level in neurodegenerative disease datasets. This simulation
framework is equally applicable to a range of other models and longitudinal analysis techniques.
© 2015 The Authors. Published by Elsevier B.V.























Neurodegenerative diseases, such as Alzheimer’s disease (AD),
untington’s disease (HD), Parkinson’s disease (PD), and amy-
trophic lateral sclerosis (ALS), present increasing social and
conomic costs. Determining the sequence and evolution of the
ymptoms and pathologies of neurodegenerative diseases will enable
re-symptomatic and differential diagnosis, and treatment monitor-
ng for drug trials. Biomarkers have been developed that allow the∗ Corresponding author. Tel.: +44 20 7679 0221.
E-mail address: alexandra.young.11@ucl.ac.uk (A.L. Young).
1
Data used in preparation of this article were obtained from the Alzheimer’s Dis-
ase Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the in-
estigators within the ADNI contributed to the design and implementation of ADNI
nd/or provided data but did not participate in analysis or writing of this report. A












361-8415/© 2015 The Authors. Published by Elsevier B.V. This is an open access article underesence and progression of these pathologies to bemeasured in vivo.
uch biomarkers include cerebrospinal ﬂuid (CSF) measures of pro-
eins implicated in disease pathogenesis, structural magnetic reso-
ance imaging (MRI) measures of regional volume changes, positron
mission tomography (PET) measures of hypometabolism or abnor-
al protein deposition, and cognitive test scores. Recentmulti-centre
ollaborations, such as the Alzheimer’s Disease Neuroimaging Ini-
iative (ADNI) for AD, the Parkinson Progression Marker Initiative
PPMI) for PD, and the Track-HD study for HD, collect a diverse set of
iomarker data from large cohorts. However, analysing longitudinal
iomarker trends in such datasets is diﬃcult due to inherent disease
eterogeneity and the long disease time course (thought to be over
decade in some cases), which means that even so-called longitu-
inal data is almost cross-sectional with respect to the full disease
uration. As a result, understanding of the longitudinal evolution of
iomarkers in neurodegenerative diseases remains largely hypothet-
cal (Aisen et al., 2010; Frisoni et al., 2010; Jack et al., 2010).r the CC BY license (http://creativecommons.org/licenses/by/4.0/).
























































vIn AD for example, the most well validated biomarkers are amy-
loid PET imaging (Clark et al., 2011; Klunk et al., 2004) and CSF Aβ1-42
(Blennow and Hampel, 2003) to measure brain amyloid pathology;
CSF total tau (t-tau) and phosphorylated tau (p-tau) (Blennow and
Hampel, 2003) to measure neuroﬁbrillary tangle (NFT) deposition
and neuroaxonal damage; FDG-PET imaging (Herholz, 2012) to mea-
sure brain hypometabolism; volumetric measures fromMRI (Fox and
Schott, 2004) to measure neurodegeneration; and a range of cog-
nitive tests to measure memory loss and other cognitive deﬁcits.
Hypothetical models of AD describe a distinct sequence in which
these biomarkers become abnormal (Jack et al., 2010). Jack et al. (Jack
et al., 2010) propose a model in which biomarkers evolve sigmoidally
over time with amyloid plaque biomarkers such as CSF Aβ1-42 and
amyloid PET preceding NFT deposition and neuroaxonal damage
markers such as CSF p-tau, CSF t-tau. These in turn become abnor-
mal prior to FDG-PET hypometabolism and grey-matter atrophymea-
sured on MRI, before ﬁnally memory and cognition are affected, as
measured using cognitive test scores. More recently, Jack et al. (Jack
and Holtzman, 2013; Jack et al., 2013a) have revised this model to
account for the possibilities that (1) NFT build up and neurodegen-
eration precede amyloid plaque development in some cases, and (2)
subjects have mixed pathology. However, these models await empir-
ical validation from measured datasets.
Data-driven models of disease progression allow longitudinal
trends to be reconstructed from cross-sectional or short-term lon-
gitudinal datasets. Basic techniques to analyse biomarker trajectories
involve staging subjects and then comparing biomarker levels across
different disease stages (Bateman et al., 2012; Caroli and Frisoni,
2010; Förster et al., 2012; Jack et al., 2011, 2012; Landau et al., 2012;
Lo et al., 2011; Sabuncu et al., 2011; Schuff et al., 2012). This limits the
temporal resolution of the model to the accuracy of the patient stag-
ing. Patient staging techniques include clinical diagnoses (Förster et
al., 2012; Jack et al., 2011; Landau et al., 2012; Lo et al., 2011), which
typically comprise just three stages: cognitively normal (CN), mild
cognitive impairment (MCI) and clinical AD; cognitive test scores
(Caroli and Frisoni, 2010; Jack et al., 2012; Sabuncu et al., 2011), which
suffer fromﬂoor and ceiling effects; age (Schuff et al., 2012), for which
disease stage varies widely amongst subjects; and predicted age of
onset based on parents age of onset (Bateman et al., 2012), which can
only be established for genetic disease subtypes and is a crude esti-
mate of actual onset. Data-driven models do not require prior knowl-
edge of the stage of a patient along the disease, allowing the recon-
struction of a much more ﬁne-grained picture of disease progression.
Differential equation models (DEM) (Jack et al., 2013b; Oxtoby et al.,
2014; Sabuncu et al., 2011; Villemagne et al., 2013) model short-term
longitudinal patient data as a differential cross-section of a common
longitudinal biomarker trajectory; the overall biomarker trajectory is
obtained by integrating all of the subject’s differential cross-sections.
Jedynak et al. (Jedynak et al., 2012) and Donohue et al. (Donohue
et al., 2014) make a similar set of assumptions to formulate their dis-
ease progression models, again modelling each subject’s biomarker
data as a snapshot of a common progression curve, but further allow-
ing for variation in individual progression rates. Another data-driven
model, the Event Based Model (EBM) (Fonteijn et al., 2012; Young
et al., 2014) considers disease progression as a sequence of events at
which biomarkers become abnormal, thereby allowing direct deter-
mination of biomarker ordering from entirely cross-sectional data.
However, such data-driven models typically depend on idealised
assumptions about the data that they are modelling. First, that all
subjects follow the same progression pattern. This is not true in
general as large cross-sectional datasets will contain subjects who
have different disease subtypes, mixed pathology, have been misdi-
agnosed, are yet to develop other diseases, or who are aging healthily.
Such outliers are particularly prevalent in pre-symptomatic popula-
tions where the diagnostic outcome is unknown. Second, a set of pa-
rameters that deﬁne normal and abnormal biomarker levels. This is aiﬃcult to determine due to the high proportions of pre-symptomatic
ubjects in typical control populations (for example, a signiﬁcant pro-
ortion of cognitively normal elderly subjects have been found to
ave biomarker changes consistent with AD (Rowe et al., 2010; Schott
t al., 2010)), and misdiagnosis in diseased populations. Third, that
he underlying disease time course is well sampled. In reality, pre-
ymptomatic subjects may not go on to develop the neurodegenera-
ive disease being investigated and therefore the early disease stages
ight be under sampled or misrepresented, and diseased subjects
ay not be representative of the very late disease stages where the
opulation thins and severe illness can make data hard to collect.
Here we present a simulation system to generate synthetic
iomarker datasets that represent the heterogeneity of sporadic neu-
odegenerative diseases. Although still based on a model of disease
rogression, it encapsulates many more variables than the simpler
odels that are parsimonious enough to ﬁt to current data sets. Thus
t provides a platform to evaluate the effect of more brutal simpliﬁ-
ations necessary to obtain robust ﬁtting results from working mod-
ls. Here, we demonstrate this simulation system by evaluating the
erformance of the EBM and a DEM in determining the sequence of
iomarker abnormality from simulated data.
. Methods
.1. Generative model of data
We assume the following generative model of sporadic disease
atasets. A set of subjects with: follow-up time points, f, from a
ollow-up distribution P(f); disease subtypes, s, from a subtype distri-
ution P(s); each set of follow-up time points correspond to a set of
ime points along the disease, t, from a time point distribution P(t|f).
t each time point a subset, e, of the biomarkers included in the study
remeasured for a particular subject according to a biomarker collec-
ion distribution P(e|f), i.e. a subset of the biomarkers included in the
tudy are measured in the subset of subjects that have a particular
ollow-up visit. Each subject has a set of biomarkermeasurements, xe,
t each time point t ∈ t. The collected biomarker measurements are
imulated from a trajectory evolution function z(t, θ) with parameters
from a trajectory parameter distribution P(θ|s, t), and measurement
oise ε perturbation from ameasurement noise distribution P(ɛ). The
ata for each collected biomarker for each patient for each time point
s then x = z(t, θ) + ε; biomarkers that are not collected are recorded
s missing data. Each subject is given a particular diagnosis d from a
iagnosis distribution P(d|xe).
.2. Simulating sporadic AD
.2.1. ADNI dataset
We used data from the Alzheimer’s Disease Neuroimaging Ini-
iative (ADNI) to guide some of the settings for the simulations.
he ADNI was launched in 2003 by the National Institute on Aging
NIA), the National Institute of Biomedical Imaging and Bioengineer-
ng (NBIB), the Food and Drug Administration (FDA), private phar-
aceutical companies and non-proﬁt organisations, as a $60 mil-
ion, 5-year public–private partnership. For up-to-date information
ee http://www.adni-info.org.
We downloaded baseline and follow-up data from all subjects
n ADNI-1 giving a set of 819 subjects (229 cognitively normal, 398
ild cognitive impairment, 192 Alzheimer’s disease). We included
he following set of biomarker data: CSF Aβ1-42, CSF t-tau, CSF p-tau;
he Mini Mental State Examination (MMSE) (McKhann et al., 1984);
aseline MRI volumes of whole brain, hippocampus and ventricles;
DG-PET. MRI volumes were corrected for differences in head size by
egressing against total intracranial volume (TIV). FDG-PET uptake
alues were averaged over the angular gyrus, inferior temporal gyrus,
nd posterior cingulate gyrus. For simplicity we only model baseline





























FSF, as modelling longitudinal CSF requires a new set of measure-
ents for each time point to be modelled, as all the CSF measure-
ents are re-processed once a new follow up is completed.
.2.2. Generic AD simulation model
We start from a generic model of AD, adapting the settings to per-
orm a stability analysis of the EBM and DEM.
Our generic model of AD is based on the following assumptions:
• At baseline a set of time points t0 are sampled from a uniform
baseline time point distribution P(t0) = Uni f (0, tr), where tr is
the range of the initial subject time points.
• The follow-up time points are sampled sequentially from a set of
possible follow-up times under the assumption that a proportion,
rf, of subjects drop out per year.
• The time points are assumed to follow a normal distribu-
tion centred around the time after follow-up, i.e. P(t| f ) =
Norm( f + t0, σt).
• The subtype distribution is P(s) = Cat(ps,m), where ps is the prob-
ability that a subject is assigned subtype s. By default there is only
one disease subtype and so all subjects follow the typical AD set of
biomarker trajectories. Alternative subtypes are used to simulate
subjects that do not follow the typical AD sequence of biomarker
abnormality, e.g. subjects with other neurodegenerative diseases
or who are aging normally.
• The collected subset of biomarkers, e, is sampled sequentially for
the available time points by modelling an initial proportion of
subjects, pe, in which the biomarker is collected and a drop out
rate per year, re, i.e. of the subjects that remain in the study,
only a proportion of these have a measurement for a particular
biomarker.
• The trajectory evolution function is sigmoidal, as has been hy-
pothesised by Jack et al. (Jack et al., 2010), with parameters θ =
(a, r, c, g), where a is the trajectory minimum, r the range (dif-
ference between trajectory maximum and minimum value), c the
centre point and g the gradient. To make the magnitude of the
gradient a more intuitive quantity, we re-parameterise g so that
it is the biomarker ‘transition time’. We deﬁne this as τ = 4/g, i.e.
it is the time taken for the tangent to the sigmoid at the centre
point, c, to transition from the minimum biomarker value, a, to
the maximum biomarker value, a + r. Hence, we have
z(t, θ) = a + r
1 + exp
(
− 4τ (t − c)
) ,
with parameters θ = (a, r, c, τ ).
• The trajectory parameters are normally distributed according to
the trajectory parameter distributions:
◦ P(a) = Norm(μa,a)
◦ P(r) = Norm(μr,r)
◦ P(c|s) = Norm(μc,s,c)
◦ P(τ) = Norm(μτ ,τ )
The parameters μa, μr, μc, s, μτ are the trajectory parameter
eans; a, r, c, τ are the inter-subject covariances of the tra-
ectory parameters.
• Themeasurement noise distribution follows a normal distribution
with mean 0 and standard deviation υ , i.e. P(ε) = Norm(0, υ)
• There are three diagnoses, d = {CN, MCI, AD}, as there are
in ADNI, that follow a categorical distribution: P(d|x) =
Cat(pCN, pMCI, pAD), where pCN is the probability that a subject
is assigned a CN diagnosis, pMCI is the probability that a sub-
ject is assigned a MCI diagnosis, and pAD is the probability that
a subject is assigned an AD diagnosis. The probability of each
diagnosis pd is evaluated using each subjects biomarker data, x,
as pd ∝
∏I
i=1 Norm(xi,μd,i, σd,i).We tested the agreement between data sets generated using the
efault parameter values and ADNI by calculating the Bhattacharyya
oeﬃcient (Bhattacharyya, 1943), BC, between simulated data sets
nd data from ADNI. The Bhattacharyya coeﬃcientmeasures the sim-
larity between two probability distributions, ranging from 0 to 1,












= ADNI + simulated
2
The Bhattacharyya coeﬃcient, BC, is BC = exp(−DB).
We ﬁnd that data sets generated using the default parameters val-
es show good agreement with the ADNI data set, giving an average
hattacharyya coeﬃcient across 25 sample data sets of 0.99 when
onsidering the biomarkers to be independent, and 0.83 when con-
idering the dependence between biomarkers.
.2.3. Datasets for EBM stability analysis
We use our generic AD model to perform a set of simulations
o assess how robust the EBM and DEM are to different choices of
arameters.
For these experiments we assume the following set of default pa-
ameters (Table 1, Fig. 1). These default parameters are intended as
n idealised basis for the stability analysis, from which each param-
ter can be varied individually so as to explore the robustness of the
odels to variations in a particular parameter, independently of other
ffects. For each experiment we generate synthetic datasets that have
00 subjects and the biomarker set: CSF Aβ1-42, CSF t-tau, CSF p-tau,
DG, MMSE, hippocampal volume, brain volume, ventricular volume.
• Baseline time points: tr = 20, i.e. there is a range of 20 years in
which a subject’s baseline visit might lie.
• Follow-ups: There are 11 possible follow-up times, as there are in
ADNI, at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, and 9 years from baseline. The
drop out rate per year, rf, is estimated from ADNI as 10%.
• Time points: the standard deviation, σ t, of the actual time at
which each follow-up is taken is approximated from ADNI as
σt = 0.05 for t = 0.5, 1, 1.5, and σt = 0.1 for t ≥ 2 (at baseline
σt = 0).
• Subtype: ps=1 = 1, i.e. all subjects have the same disease subtype
by default.
• Biomarker collection: The proportion of subjects in which each
biomarker is collected at baseline, pe, and the drop out rate per
year, re, are estimated from ADNI as pe = 100%, 85%, 55%, 50%,
and re = 0%, 10%, 5%, 100% for cognitive test scores, MRI volumes,
FDG-PET hypometabolism, and CSF levels respectively (i.e. only
baseline CSF modelled).
• Trajectory parameters: μa is estimated from the mean biomarker
value in cognitively normal subjects from ADNI (Table 1). μr is
estimated as the difference between the mean biomarker value
in Alzheimer’s disease and cognitively normal subjects from ADNI
(Table 1). For CSF Aβ1-42 we use only amyloid negative cognitively
normal subjects, and amyloid positive Alzheimer’s disease sub-
jects (amyloid positive is deﬁned as CSF Aβ1-42 < 192 pg/ml). We
chose settings for μc so that the biomarkers become abnormal
in the order: Abeta, p-tau, t-tau, FDG-PET, hippocampal volume,
MMSE, ventricles, whole brain volume (Table 1). We set μτ to
5 years for all biomarkers (Table 1).
• Trajectory inter-subject covariance: a is estimated from the set
of 28 amyloid negative cognitively normal ADNI subjects at base-
line that have measurements for all biomarkers (Table 1), we re-
move the contribution of measurement noise by subtracting the
50 A.L. Young et al. /Medical Image Analysis 26 (2015) 47–56
Table 1
Default parameter values for the EBM. μa = mean trajectory minimum, μr = mean trajectory range, μc = mean trajectory centre
point (years), μτ = mean trajectory transition time (years). υ2μ2r = biomarker measurement variance, normalised by the range of
the trajectory. a/μrμrT = covariance of the trajectory minimum, normalised by the range of the trajectory. All other covariance
matrices are set to 0 by default.
Abeta p-tau t-tau FDG Hippo MMSE Vents Brain
μa 243 20 63 6.39 903 29.1 −7400 34300
μr −110 23 63 −1.01 −1630 −5.78 13600 −64000
μc 5 6 7 8 10 12 14 15
μτ 5 5 5 5 5 5 5 5
υ2/μ2r 0 0 0 0.030 0.006 0.013 0.004 0.022
a/μrμTr Abeta 0.058 0.001 −0.004 0.014 −0.001 0.002 0.013 0.007
p-tau 0.150 0.126 0.041 −0.069 −0.015 0.048 −0.106
t-tau 0.178 0.031 −0.084 −0.003 −0.013 −0.068
FDG 0.308 0.064 0.008 −0.191 0.109
Hippo 0.198 −0.007 −0.320 0.326





































testimated measurement variance level (see next bullet point). By
default we set r = 0, c = 0, τ = 0.
• Measurement noise: We estimate the measurement noise level υ
for each biomarker using baseline and 6 month follow-up mea-
surements in cognitively normal subjects from ADNI (Table 1) un-
der the assumption that ﬂuctuations in controls over a 6 month
period are representative of measurement noise. For CSF we only
have baseline measurements and so we set the measurement
noise to 0, i.e. wemodel the variance as being purely inter-subject
covariance rather than removing the contribution of measure-
ment noise as we do for the other biomarkers.
• Diagnosis:We estimateμd and σ d for each diagnostic group using
the available data for each biomarker from ADNI.
In the experiments we vary each of the following parameters of
the simulations in turn, and set the rest of the parameters to their de-
fault value, generating 25 synthetic datasets for each new parameter
value, and ﬁtting the EBM to each sample dataset.
2.2.3. Datasets for DEM stability analysis
For the DEM experiments we initially ﬁtted a DEM to each
biomarker using the default simulation settings for the EBM. How-
ever, these experiments show that the DEM does not perform well
for the levels of noise estimated from ADNI. We therefore simplify
the default settings for the DEM to allow us to characterise the types
of noise the DEM ismost sensitive to. By default we instead generate a
single idealised (zero noise) biomarker trajectory with the following
settings.
• Biomarker collection: pe = 100%, re = 0%.
• Trajectory parameters: μa = 0, μr = 1, μc = 10, μτ = 5.
• Trajectory inter-subject covariance: a = 0, r = 0, c = 0,
τ = 0.
• Measurement noise: υ = 0.
In the experiments we again vary each of the following param-
eters of the simulations in turn, and set the rest of the parameters
to their default value, generating 25 synthetic datasets for each new
parameter value, and ﬁtting the DEM to each sample dataset.
2.3. The Event Based Model
The Event Based Model (EBM) (Fonteijn et al., 2012) considers dis-
ease progression as a sequence of events at which biomarkers transi-
tion from a normal level, i.e. as seen in healthy controls, to an abnor-
mal level, i.e. as seen in AD subjects. The maximum likelihood (ML)rdering of these events can be determined by ﬁnding the sequence
















Here, Ei, i = 1 . . . I, are events, whose occurrence is informed by
he corresponding measurements xij of biomarker i in subject j, j =
. . . J via the biomarker distributions: the likelihood that an event
as occurred and thus the corresponding biomarker measurement xij
s abnormal, P(xij|Ei), or has yet to occur and so the corresponding
iomarker measurement is normal, P(xij|Ei). P(k) is the prior likeli-
ood of being at stage k, where events E1, . . . , Ek have occurred, and
vents Ek+1, . . . , EK have yet to occur. We assume no prior knowledge
f disease stage by choosing the prior P(k) to be uniform.We ﬁt amix-
ure of normal distributions to determine the mean, μE and μ¬E , and
tandard deviation, σ E and σ¬E , of the biomarker distributions P(x|E),
nd P(x|¬E). To guide the ﬁtting in cases where the biomarker dis-
ributions overlap signiﬁcantly, we constrain the parameters so that
he standard deviation of each distribution is less than or equal to the
tandard deviation of biomarker measurements in the AD and con-
rol (CN) population respectively. For missing biomarker values we
mpute the value of x such that P(x|E) = P(x|¬E).
.4. Differential equation model
We ﬁt the DEM to each biomarker separately using a similar tech-
ique to Villemagne et al. (Villemagne et al., 2013). We ﬁrst calculate
he rate of change in each subject by ﬁtting a least-square linear re-
ression to the ﬁrst three available time points for each participant.
or each simulation we compared ﬁtting a linear model to the ﬁrst
hree available time points (baseline, 0.5 years and 1 year) with ﬁt-
ing a linear model to the three or more available time points (up to
maximum of 9 years). We found that ﬁtting the linear model to the
rst three available time points produced trajectories with the least
rror for all experiments, and so we only present results for ﬁtting
o the ﬁrst three available time points. We ﬁt a quadratic differential
quation model (representative of the sigmoidal biomarker dynam-
cs modelled in the simulations) to the mean biomarker value of each








= Axi2 + Bxi +C
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Fig. 1. Example simulated FDG-PET, subject diagnosis, and time point data generated using default parameter values for the EBM (Table 1). (A) Simulated baseline FDG-PET data
(curve shows mean trajectory); (B) simulated FDG-PET follow-up data for cognitively normal subjects (green), mild cognitive impairment subjects (blue), and Alzheimer’s disease
subjects (red); (C) same as (B) but plotted against follow up time rather than time point along the disease. (D)–(F) Histogram of the number of (D) cognitively normal, (E) mild
cognitive impairment and (F) Alzheimer’s disease subjects, at each time point at baseline. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred




















dWe then integrate this quadratic differential equationmodel to get
he average trajectory across the population:
(t) =
√
4AC − B2 tan
(
1






here k is an unknown constant to be speciﬁed by choosing an initial
ondition.
.5. Evaluation metrics
.5.1. EBM biomarker distribution parameters
Deﬁning a ground truth for the biomarker distribution parame-
ers when the biomarker trajectories are not binary is not straight-orward, requiring the portion of the biomarker trajectory belong-
ng to the ‘normal’ and ‘abnormal’ biomarker distribution to be
eﬁned. However, to explore the effect of the accuracy of the
iomarker distribution on the estimation of the event sequence we
an each of the experiments for two settings: one where we esti-
ated the biomarker distributions and another where these were
xed. We ﬁx the biomarker distributions so that μ¬E = μa, μE =
a + μr , σ¬E = σE =
√
diag(a) + υ2, where diag() is the di-
gonal of the covariance matrix . μa, m and μb, m are calculated
rom the average subject demographics. Whilst these may not be
he ‘true’ biomarker distribution parameters, they give us an idea
f how the EBM behaves for a reasonable setting of the biomarker
istribution parameters.
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Fig. 2. Results of applying the EBM to synthetic data with missing values (A)–(B) and without missing values (C)–(D) generated using the default parameters. In (A) and (C) the























(2.5.2. EBM Kendall’s tau distance
A key outcome measure we are interested in is the model’s abil-
ity to recover the ML sequence from the simulated data. This can be
evaluated by measuring the Kendall’s tau distance (a measure of the
similarity of two sequences) between the recovered sequence and a
ground truth event sequence. The Kendall’s tau distance is the total







where π and π0 are permutations and l≺π j means that l precedes
j in the permutation π . Here we use the normalised Kendall’s tau
distance, i.e. we divide by the maximum distance, which is the total
number of possible pairs: n!
2!(n−2)! , where n is the number of events
in the sequence.
2.5.3. EBM positional variance diagrams
We use positional variance diagrams (PVDs) to look at the loca-
tion of variations in the ML sequence (rather than just the extent,
which we measure using the Kendall’s tau distance) for each simula-
tion. Each entry of the positional variance diagram is the proportion
of samples in which a particular event appears at that position in the
ML sequence.
2.5.4. DEM transition time
We compare the transition time of the simulated trajectories
across the population with the ground truth simulation setting of the
transition time, μτ .. Results
.1. EBM stability analysis
We performed a stability analysis of the EBM to test how robust
he model is to different types of heterogeneity that are likely to exist
n sporadic AD datasets.
.1.1. Default parameter values
Fitting the EBM to datasets generated using the default parameter
alues (Fig. 2) gives a Kendall’s tau distance of 0.11 ± 0.05 when esti-
ating the event distributions from the data, and 0.01± 0.01 for ﬁxed
vent distributions. Repeating this experiment without any missing
iomarker values only slightly improves the Kendall’s tau distance
espite the increase in the number of data points; 0.10 ± 0.09 for es-
imated event distributions, and 0.00 ± 0.01 for ﬁxed event distribu-
ions, showing that imputing the data such that P(x|E) = P(x|¬E) (see
ection 2.3) is a valid technique for ﬁtting the EBM to data with miss-
ng biomarker values. It is worth noting that in all the simulations the
nter-subject variation setting, which is estimated from ADNI, may be
arger than the actual level of inter-subject variation. This is because
ognitively normal subjects in ADNI may originate from a range of
nderlying time points along the biomarker trajectories.
.1.2. Experiment 1: Noise levels
We ran ﬁve simulations to look at the effect of different levels
f: (A) measurement noise υ , (B) inter-subject covariance of the tra-
ectory minimum a, (C) inter-subject covariance of the trajectory
ange r, (D) inter-subject covariance of the trajectory centre c, s,
E) inter-subject covariance of the trajectory transition time τ . For
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Table 2
Mean (standard deviation of the mean in brackets) Kendall’s tau distance between ground truth event se-
quence and event sequence returned by the EBM for synthetic data with varying: (A) noise levels, (B) tra-
jectory parameters, (C) time sampling, (D) subtypes. In all tables each column is a new parameter value,
and ‘estimated’ and ‘ﬁxed’ refer to whether the event distributions are estimated by the EBM or ﬁxed to
known values. Bold values represent the default parameters of the EBM. In part (A), experiments A–E rep-
resent varying: A. measurement noise; B. inter-subject covariance of trajectory minimum; C. inter-subject
covariance of trajectory range; D. inter-subject covariance of trajectory centre; E. inter-subject covariance
of trajectory transition time. In part (B), experiments A–B represent varying: A. trajectory centre points, B.
trajectory transition times.
A. Noise levels
0.01 0.1 0.5 1 2
Estimated A 0.10 (0.06) 0.09 (0.05) 0.11 (0.06) 0.10 (0.05) 0.12 (0.05)
B 0.12 (0.06) 0.00 (0.01) 0.02 (0.02) 0.09 (0.05) 0.36 (0.16)
C 0.11 (0.05) 0.11 (0.06) 0.13 (0.06) 0.20 (0.17) 0.18 (0.17)
D 0.09 (0.05) 0.13 (0.04) 0.24 (0.17) 0.32 (0.12) 0.47 (0.18)
E 0.10 (0.05) 0.09 (0.04) 0.15 (0.10) 0.26 (0.12) 0.40 (0.11)
Fixed A 0.00 (0.01) 0.00 (0.01) 0.01 (0.02) 0.01 (0.01) 0.01 (0.02)
B 0.17 (0.04) 0 (0) 0.00 (0.01) 0.00 (0.01) 0.07 (0.04)
C 0.00 (0.01) 0.01 (0.01) 0.03 (0.04) 0.11 (0.04) 0.17 (0.10)
D 0.00 (0.01) 0.01 (0.01) 0.05 (0.04) 0.09 (0.05) 0.17 (0.05)
E 0.01 (0.02) 0.01 (0.01) 0.01 (0.02) 0.10 (0.06) 0.19 (0.06)
B. Trajectory parameters
1 5 10 15 20
Estimated A 0.44(0.21) 0.19 (0.04) 0.09 (0.04) 0.08 (0.15) 0.20 (0.22)
B 0.03 (0.02) 0.11 (0.05) 0.19 (0.04) 0.24 (0.05) 0.30 (0.12)
Fixed A 0.38 (0.22) 0.09 (0.04) 0.01 (0.01) 0 (0) 0.01 (0.01)
B 0.00 (0.01) 0.00 (0.01) 0.01 (0.03) 0.04 (0.04) 0.05 (0.03)
C. Time sampling
0 1 2.5 5
Estimated 0.12 (0.06) 0.10 (0.06) 0.11 (0.07) 0.10 (0.04)
Fixed 0 (0) 0.00 (0.01) 0 (0) 0.00 (0.01)
D. Subtypes
0 0.25 0.5 0.75 1
Estimated 0.10 (0.04) 0.17 (0.20) 0.50 (0.36) 0.91 (0.06) 0.96 (0.05)




















































(ach of the respective simulations we vary the noise level as a pro-
ortion p of (A) the estimated measurement noise from ADNI (see
ection 2.2.3 and Table 1), and as a proportion p2 of the covariance
atrices: (B) the estimated inter-subject covariance of the trajectory
inimum from ADNI (see Section 2.2.3 and Table 1), (C) the square
f the mean of the trajectory range μr2 estimated from ADNI (see
ection 2.2.3 and Table 1), (D) the range of the trajectory centre points
quared, 102 years, (E) the range of the baseline time points squared,
02 years. For simulations (C), (D), and (E) we assume a diagonal co-
ariance matrix. Varying the measurement noise υ (Table 2A: Exper-
ment A) has little effect on the Kendall’s tau distance between the
ample event sequences and the ground truth as the estimated mea-
urement noise level is small compared to the inter-subject covari-
nce of the trajectory minimum (Table 1). Varying the inter-subject
ovariance of the trajectory minimum a (Table 2A: Experiment B)
as a large effect on the Kendall’s tau distance for the estimated event
istributions, but little effect for ﬁxed event distributions. This shows
hat it is diﬃcult to estimate the parameters of the event distributions
or high biomarker inter-subject variance levels. For very low vari-
nce levels on a the Kendall’s tau distance increases again for both
xed and estimated event distributions. This is probably because at
ery low variance the event distributions do notmodel the biomarker
alues over the central portion of the biomarker trajectory, where the
rajectory transitions from the minimum to the maximum value. This
akes it ambiguous as to whether the biomarker is normal or abnor-
al during the trajectory transition, making it diﬃcult for the EBM
o order the biomarkers. The EBM is robust to inter-subject variationn the trajectory range r (Table 2A: Experiment C), giving a similar
endall’s tau distance to the default settings for noise levels up to 50%
f the range μr. The EBM is quite robust to variation in the trajectory
entre points c, s (Table 2A: Experiment D) and transition time τ
Table 2A: Experiment E).
.1.3. Experiment 2: Trajectory parameters
We performed two experiments to test the robustness of the EBM
o different values of the trajectory parameters: (A) varying the cen-
re points of the trajectories, μc, and (B) varying the transition time
f the trajectories μτ . In (A) we assume an evenly spaced set of tra-
ectory centre points over a segment of the disease time course. We
ary the duration of this segment as a fraction of 10 years. The tra-
ectory centre points are centred about the middle point along the
isease time course (10 years). In (B) we vary the transition time as a
raction of the overall range of the disease time course (20 years),
eeping the transition time the same for all biomarkers. The EBM
as diﬃculty estimating the event sequence for both ﬁxed and es-
imated event distributions when the trajectory centres are close
ogether (Table 2B: Experiment A), and for longer transition times
Table 2B: Experiment B), which violate the assumption of the EBM
hat an event has either occurred or not occurred. For estimated event
istributions the EBM also has diﬃculty ordering the events when
he trajectory centres are spread over the full disease time course
Table 2B: Experiment A). This is because the portion of the trajectory
here the biomarker is normal (for early biomarkers) or abnormal
for late biomarkers) is not observed. As in the previous experiments,
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Fig. 3. Integrated DEM trajectories for FDG-PET uptake generated using synthetic data
with the default settings for the EBM (Table 1). The ground truth trajectory is in red,
and the median estimated trajectory is in black with the inter-quartile range shaded in
grey. (For interpretation of the references to colour in this ﬁgure legend, the reader is
referred to the web version of this article.)
Table 3
Mean (standard deviation of the mean in brackets) estimated transition time
(years) for DEM ﬁtted to synthetic data with varying: A. measurement noise;
B. inter-subject variance of trajectory minimum; C. inter-subject variance of
trajectory range; D. inter-subject variance of trajectory centre; E. inter-subject
variance of trajectory transition time. For all simulations the ground truth tran-
sition time is 5 years. Each column is a new parameter value.
0.1 0.25 0.5 1
A 5.9 (0.4) 9.8 (3.1) 12.7 (4.7) 15.0 (5.2)
B 7.5 (0.2) 11.4 (0.5) 13.3 (0.5) 14.4 (0.7)
C 6.6 (0.2) 9.8 (0.5) 11.6 (0.7) 12.3 (1.0)
D 5.1 (0.0) 5.1 (0.0) 5.1 (0.0) 5.1 (0.0)





















aﬁxing the event distributions improves the estimation of the event
sequence.
3.1.4. Experiment 3: Time sampling
In this experiment we look at how under-sampling of the disease
time course affects the ability of the EBM to recover the sequence
of biomarker abnormality. We assume that the time points are sam-
pled from a mixture of three Gaussian distributions, with means at
5 years, 10 years and 15 years respectively. We vary the standard de-
viation of these distributions, assuming that all of the Gaussians have
the same standard deviation. This allows us to simulate the case that
cognitively normal, mild cognitive impairment and Alzheimer’s dis-
ease subjects are at entirely different points along the disease time
course. The EBM is robust to under-sampling of the disease time
course (Table 2C), giving a similar Kendall’s tau distance to the de-
fault settings for all simulations.
3.1.5. Experiment 4: Subtypes
To explore the effect of including a set of subjects that follow a dif-
ferent event sequencewemodelled two disease subtypes, varying the
fraction of subjects that belong to each subtype. For both subtypes the
trajectory centre points are evenly spaced from aminimum of 5 years
to a maximum of 15 years. In subtype 1 the biomarkers become ab-
normal in the same order as the default settings: Abeta, p-tau, t-tau,
FDG-PET, hippocampal volume, MMSE, ventricles, whole brain vol-
ume. In subtype 2 the biomarkers become abnormal in the reverse
sequence. This sequence has a Kendall’s tau distance of 1 from the se-
quence of subtype 1. The EBM is robust up to a proportion of 25% of
subjects that follow an alternative event sequence (Table 2D): at 25%
outliers the Kendall’s tau distance is similar to the result for 0% out-
liers for estimated event distributions, and only slightly increased for
ﬁxed event distributions. Likewise, at 75% outliers, when the major-
ity of subjects are subtype 2 the Kendall’s tau distance is only slightly
worse than for 100% outliers. At 50% outliers the EBM alternates be-
tween estimating a sequence similar to subtype 1 and subtype 2.
3.2. DEM stability analysis
We performed a stability analysis of the DEM to test how robust
the model is to varying the noise levels on the trajectory parameters.
3.2.1. Default parameter values
Fitting a DEM to each biomarker in turn (see Fig. 3 for estimated
synthetic trajectories for FDG-PET) using the default parameter val-
ues for the EBM gives an average across biomarkers (excluding CSF
for which we only modelled baseline collection) of a mean sample
transition time 12.8 ± 1.1 years and standard deviation of this sample
transition time of 2.2 ± 1.2 years. This is more than double the simu-
lated trajectory transition time of 5 years. For biomarkers with more
data points available (higher biomarker collection rate, e.g. MMSE)
the standard deviation of the transition time reduces but the mean
transition time remains similar, i.e. the DEM becomesmore conﬁdent
in the biased estimate of the trajectory transition time. In subsequent
experiments we simplify the default parameter settings for the DEM
to a zero noise case (see Section 2.2.3) to allow us to characterise the
types of parameter noise that the DEM is most sensitive to.
3.2.2. Stability of the DEM to noise
For the DEM default parameter values (zero noise case) the DEM
is able to recover the trajectory transition timemuchmore accurately
(sample transition time is 5.1 ± 0.0 years for a simulated trajectory
with a transition time of 5 years). As with the EBM, we ran ﬁve simu-
lations to look at the effect of different levels of: (A) measurement
noise υ , (B) inter-subject variance of the trajectory minimum a,
(C) inter-subject variance of the trajectory range r, (D) inter-subject
variance of the trajectory centrec, s, (E) inter-subject variance of therajectory transition time τ . We vary the noise level as a proportion
of (A) μr, and a proportion p2 of the variance: (B) μr2, (C) μr2, (D)
τ
2, (E) μτ 2. The DEM is sensitive to measurement noise (Table 3A:
xperiment A), and variance of the trajectory minimum (Table 3A:
xperiment B) and range (Table 3A: Experiment C), with 25% mea-
urement noise giving a transition time of around twice as long as
he actual transition time. The DEM is less sensitive to variance of the
rajectory transition time (Table 3A: Experiment E). The DEM is unaf-
ected by noise in the trajectory centre point (Table 3A: Experiment
), as this is removed by differentiating.
. Discussion
We have presented a framework for the simulation of sporadic
eurodegenerative disease datasets. We applied the framework to
enerate synthetic Alzheimer’s disease data, and thereby provide in-
ight into the robustness of the EBM and a DEM to the likely variation
n sporadic disease datasets.
.1. Simulation framework
The simulation framework we have presented is simple and ﬂex-
ble. For example, it is easily extendible to include subjects with a
ange of demographics, for example age, gender, and education, or
enetic risk factors. Such effects can be modelled as a transforma-
ion of the trajectory parameters. Here we simplify the diagnosis as
relationship with the biomarker values, however, a more realistic















































































































Ciagnosis procedure could be simulated that is based on, for example,
ognitive test results. It is also possible to add in a screening proce-
ure that post-selects subjects with a similar set of demographics to
he dataset being simulated, for example age matching across diag-
ostic categories. Here we only consider inter-subject variance, how-
ver, intra-subject variance for longitudinal datasets could also be
odelled.
.2. Stability analysis
.2.1. EBM stability analysis
The EBM stability analysis shows that the EBM is sensitive to the
stimation of the event distribution parameters. However, when the
vent distribution parameters are estimated accurately, the EBM is
ery robust to the likely heterogeneity in sporadic disease datasets.
e ﬁnd that the EBM is robust to noise in the trajectory parameters,
ifferent choices of trajectory parameters, under-sampling of the un-
erlying disease time course, and outliers who follow different event
equences.
.2.3. DEM stability analysis
For all simulations the DEM underestimates the trajectory gradi-
nt leading to an over estimation of the trajectory transition time. For
he level of noise estimated from the ADNI data this over estimate
s more than twice as long as the ground truth trajectory transition
ime. Whilst this result may be in part due to an over estimation of
he amount of inter-subject variation fromADNI, the stability analysis
f the DEM shows the DEM will severely over-estimate the trajectory
ransition time even when the inter-subject variation is much lower.
he DEM is very sensitive to measurement noise and inter-subject
ariation of the trajectory minimum (normal biomarker level) and
ange (difference between a normal and abnormal level). We further
nd that using three time points to ﬁt the DEM rather than all avail-
ble time points, for which the approximation to the derivative is less
alid, gives a better estimate of the trajectory transition time, even
nder high noise levels.
.2.4. Limitations
In the set of experiments presented we vary each parameter in
urn. However, there will likely be multiplicative effects of vary-
ng these parameters in combination. We further make a set of as-
umptions that are speciﬁc to hypothetical models of AD, such as
igmoidal trajectories, and to the design of the ADNI dataset, such as
he proportion of subjects that drop out per year, and the proportion
f subjects in which each biomarker is collected. Othermodels for the
ynamics of the biomarker trajectories, such as statistical time-series
odels, are easy to incorporate into the simulation framework and
ould be interesting to consider in future work. We also assume that
easurement errors are Gaussian, which may not be the best choice
f noise distribution for all of the biomarkers. Therefore, although
hese simulations do provide an insight into the types of effects that
an be expected from different datasets, the simulations should be
e-run with dataset speciﬁc parameters to assess the performance of
he EBM and DEM on alternative datasets. We chose the DEM to be
imilar to (Villemagne et al., 2013), however other DEM approaches
e.g. Oxtoby et al., 2014) may recover a more accurate estimate of the
rajectory transition time for heterogeneous data sets, and should be
ested in future work.
.3. Implications for the application and development of
ata-driven models
.3.1. The Event Based Model
The results of the EBM stability analysis show that the EBM is sen-
itive to the accuracy of the estimated biomarker distribution mod-ls, P(x|E), and P(x|¬E). Therefore the application of the EBM is most
ffective when the biomarkers have distinct control and case dis-
ributions. The results further show that the EBM is robust to 25%
utlier corruption, which is higher than the proportion of misdiag-
oses we expect in typical sporadic neurodegenerative disease co-
orts. The simulations highlight several key areas for improvement of
he EBM. First, better estimation techniques for the biomarker distri-
ution parameters should aid recovery of the event sequence when
he control and case distributions are not well deﬁned. Adaptation
f the EBM to take into account the uncertainty in the biomarker
istribution parameters, e.g. by sampling the distribution parame-
ers simultaneously with the ordering, may also help to ameliorate
his problem. Second, although the EBM can estimate the ML event
equence for a modest proportion of outliers, it is unable to distin-
uish other likely event sequences in the data. Future work will look
t ﬁtting mixture models with multiple event sequence modes to
he data (Young et al., 2015).
.3.2. Differential equation models
The simulations show that the DEM is sensitive to noise, leading
o over estimation of the trajectory transition time, meaning that the
EM should only be applied to biomarkers with low measurement
oise and inter-subject variance. Alternatively, robust ﬁtting tech-
iques need to be developed that can correct for the bias encoun-
ered when ﬁtting a DEM to noisy biomarker trajectories. The sim-
lations further show that it is important that the duration of follow
p for each individual is a good approximation to the derivative (short
ith respect to the full disease time course). This is shown to bemore
mportant than the inclusion of lots of follow up time points, which
mproves the accuracy of the estimated derivative, suggesting that
ollow up data over a longer time period should be discarded when
tting a DEM.
. Conclusion
We have presented a framework for generating synthetic neu-
odegenerative disease datasets, which can be used to evaluate the
obustness of data-driven models to likely variations in sporadic dis-
ase datasets, and to directly compare them. We have demonstrated
he use of this framework to evaluate the stability of the EBM and
DEM of disease progression to heterogeneity in the ADNI dataset.
uture work will use the simulation framework to evaluate the sta-
ility of other data-driven models, such as self-modelling regression
pproaches (Donohue et al., 2014). The simulation framework can fur-
her be used as a technique for validating extensions to data-driven
odels, to determine model weaknesses, and to highlight areas for
mprovement and future work.
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